Muscimol is the primary psychoactive compound in Amanita muscaria mushrooms, and it works by activating the same receptors in your brain that respond to GABA, your nervous system’s main “slow down” signal. The result is a combination of sedation, euphoria, altered sensory perception, and visual hallucinations that feels distinctly different from other psychoactive substances. Unlike psilocybin mushrooms, which stimulate serotonin receptors, muscimol’s effects are rooted in the inhibitory side of brain chemistry.
How Muscimol Works in the Brain
Your brain constantly balances excitation and inhibition. GABA is the chief inhibitory neurotransmitter, responsible for calming neural activity, and it works by binding to GABA-A receptors on the surface of neurons. Muscimol mimics GABA at these receptors, essentially telling your neurons to quiet down. This is the same receptor family targeted by sedatives like benzodiazepines and barbiturates, though muscimol binds to a different site on the receptor.
For years, muscimol was treated as a non-selective GABA-A agonist, meaning researchers assumed it activated all subtypes of the receptor equally. That turns out to be wrong. Research published in the Journal of Neurochemistry found that muscimol has exceptionally high affinity for a specific subtype containing what’s called the delta subunit. These delta-containing receptors sit outside the main communication points between neurons and are responsible for a steady, background level of inhibition in the brain. Muscimol binds to them at concentrations in the low nanomolar range, far lower than what’s needed to activate other GABA-A subtypes. When researchers deleted the gene for the delta subunit in mice, the animals showed drastically reduced sensitivity to muscimol, confirming that these receptors are the primary target at lower doses.
This selectivity matters because delta-containing receptors are concentrated in areas like the forebrain (involved in cognition and sensory processing) and the cerebellum (which controls coordination and balance). That distribution helps explain the specific pattern of effects muscimol produces.
What Muscimol Feels Like
The experience of muscimol is often described as dream-like and sedating, quite different from the energized, visual trips associated with psilocybin. Common effects include euphoria, dizziness, heightened or distorted sensory perception, impaired coordination, and visual hallucinations. Because muscimol acts on the cerebral cortex, thalamus, hippocampus, and cerebellum simultaneously, the effects span mood, perception, memory, and physical movement.
The sedation can be heavy. Some people describe a state somewhere between waking and sleeping, with vivid imagery and a sense of detachment from the body. Coordination suffers noticeably. Animal studies using localized muscimol injections in the brain’s motor areas show that it impairs the ability to perform fine finger movements, weakens grip strength, and disrupts the coordination needed for precise grasping. In sensory areas, it interferes with the brain’s ability to process touch feedback, making physical tasks feel clumsy and uncontrolled. These findings line up with the stumbling, uncoordinated movement commonly reported by people who consume Amanita muscaria.
Effects typically begin within 30 minutes to two hours after ingestion. Both muscimol and its precursor, ibotenic acid, cross the blood-brain barrier readily and appear in urine within an hour of exposure. The full experience generally lasts four to eight hours, though drowsiness can linger longer.
Ibotenic Acid and the Conversion Process
Muscimol doesn’t exist alone in Amanita muscaria. The mushroom also contains ibotenic acid, a neurotoxic compound that acts as an excitatory agent in the brain. Ibotenic acid is essentially the precursor to muscimol: through a chemical process called decarboxylation, ibotenic acid loses a carbon dioxide molecule and becomes muscimol.
This conversion happens slowly under normal conditions. At room temperature in water, ibotenic acid is remarkably stable, showing only about 0.2% conversion over two weeks. Even at body temperature overnight, researchers found minimal breakdown. The process speeds up significantly at boiling temperatures and extreme pH levels (very acidic or very basic), but still requires hours. This is why traditional preparation methods for Amanita muscaria typically involve drying and heating the mushrooms: the goal is to convert as much ibotenic acid as possible into the less toxic, more psychoactive muscimol. Consuming mushrooms without adequate preparation means ingesting a significant amount of ibotenic acid, which causes nausea, confusion, and neurotoxic effects that muscimol alone does not.
Toxicity and Safety Thresholds
Muscimol’s toxic threshold in humans is estimated at roughly 6 mg, with ibotenic acid’s threshold sitting higher at 30 to 60 mg. To put that in context, the muscimol content of a single Amanita muscaria cap varies widely depending on the specimen, its size, where it grew, and how it was prepared, making precise dosing from whole mushrooms unreliable.
In animal studies, the lethal dose is 45 mg per kilogram of body weight in rats (oral) and 2.5 mg per kilogram in mice (injected). Fatalities in humans are rare but have been documented, and reactions depend heavily on individual susceptibility that researchers haven’t fully characterized. Unlike some toxic mushrooms that destroy the liver, Amanita muscaria poisoning is generally not hepatotoxic. The primary dangers are respiratory depression from excessive sedation, aspiration during periods of unconsciousness, and the unpredictable effects of ibotenic acid when mushrooms are poorly prepared.
Legal Status
Muscimol and Amanita muscaria occupy an unusual legal position. In the United States, they are currently legal and unscheduled. The DEA classifies psilocybin (the active compound in “magic mushrooms”) as a Schedule I substance, but muscimol does not fall under this classification. This legal gray area has led to a growing market for Amanita muscaria products, including gummies and extracts sold as supplements or nootropics.
That market comes with risks. A 2024 CDC investigation found that some mushroom gummies marketed as containing Amanita muscaria actually contained unlabeled psilocybin or psilocin, both of which are Schedule I substances. The lack of regulatory oversight means product labels may not accurately reflect what’s inside, and muscimol content can vary widely between products.
Research Interest in Sleep and Neurology
Muscimol’s ability to enhance tonic inhibition, the steady background suppression of neural activity, has made it a subject of interest for conditions where the brain is overactive. GABA-A receptors are important therapeutic targets for insomnia because they rapidly inhibit neurotransmission, and muscimol activates these receptors potently. Researchers have also explored potential roles in neuroprotection, cognitive enhancement, and hormonal regulation, though this work remains preclinical.
The FDA has noted that the available scientific literature does not provide enough detail to fully characterize how muscimol is absorbed, distributed, metabolized, and excreted in humans. This gap in pharmacokinetic data is one reason muscimol hasn’t moved into formal clinical development for any condition, despite its clear and powerful effects on brain chemistry.